Company:Haleon
 | |
| Type | Public limited company |
|---|---|
| ISIN | GB00BMX86B70 |
| Industry |
|
| Predecessor | GSK Consumer Healthcare Pfizer Consumer Healthcare |
| Founded | 18 July 2022 |
| Headquarters | Weybridge, Surrey, England |
Area served | Worldwide |
Key people |
|
| Products |
|
| Brands | |
| Revenue |  £10,858 million (2022)[1] |
| £1,825 million (2022)[1] | |
 £1,119 million (2022)[1] | |
| Total assets | £34,815 million (2022)[1] |
| Total equity | £16,457 million (2022)[1] |
Number of employees | 22,000+ (2022)[2] |
| Website | www |
Haleon plc is a British multinational consumer healthcare company with headquarters in Weybridge, England .[3] It is one of the largest consumer healthcare businesses in the world, with brands including ChapStick lip balm, Sensodyne toothpaste, Panadol and Advil painkillers and Centrum vitamins.[4] The company is a global leader in over the counter medicines with a 7.3 percent market share.[5]
Haleon was established on 18 July 2022 as a corporate spin-off from GSK.[6]
Sir David Lewis is chairman, with Brian McNamara as CEO.[7] Haleon is listed on the London Stock Exchange and is a component of the FTSE 100, with a secondary listing on the New York Stock Exchange. Annual sales amounted to around £10 billion across 120 markets in 2020.[5]
History
GSK and Pfizer merged their consumer healthcare businesses in 2019.[8][9] GSK owned just over two thirds of the joint venture, and Pfizer held the remainder.[8]
GSK announced plans to spin-off Haleon in 2018, in order to give the "tired drugmaker extra focus and firepower by gearing up and hiving off the consumer division".[10]
Unilever offered £50 billion for the business in 2022, in a bid which GSK rejected.[11] Nestlé examined the possibility of a bid in conjunction with Reckitt.[12]
A proposed $600 million spin-off of the ChapStick lip care brand was mooted in 2023.[13]
In October 2023, GSK reduced its ownership share in Haleon to just over 7.4%,[14] and again in January 2024 down to 4.2%.[15]
Operations
Oral health accounted for 28.5 percent of revenue in 2021.[16]
Gross assets amounted to over £45 billion on 31 March 2022.[16]
Brands
Brands include:[17]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 "Annual results 2022". Haleon. https://www.haleon.com/content/dam/cf-consumer-healthcare/bp-haleon/en_US/documents/investors/Haleon-FY-2022-Press-release-02-March-2023.pdf.
- ↑ Sweney, Mark; Kollewe, Julia (18 July 2022). "GSK spin-off Haleon begins trading in biggest European listing in a decade". The Guardian. https://www.theguardian.com/business/2022/jul/18/gsk-haleon-begins-trading-listing-shares-market-value.
- ↑ "GSK announces independent Consumer Healthcare company is to be called Haleon | GSK" (in en-GB). https://www.gsk.com/en-gb/media/press-releases/gsk-announces-independent-consumer-healthcare-company-is-to-be-called-haleon/.
- ↑ Ralph, Alex (2 July 2022). "GlaxoSmithKline prepares to get back to basics with historic break-up". The Times. https://www.thetimes.co.uk/article/three-centuries-of-gsk-story-about-to-add-a-new-chapter-3jrbn8kkq.
- ↑ 5.0 5.1 Cornell, Joe (15 July 2021). "GlaxoSmithKline To Spin-Off Consumer Healthcare Business By Mid-2022". Forbes. https://www.forbes.com/sites/joecornell/2021/07/15/glaxosmithkline-to-spin-off-consumer-healthcare-business-by-mid-2022/?sh=723ac83372d0.
- ↑ "Prospectus". GSK plc. p. 15. https://www.gsk.com/media/7702/haleon-plc-prospectus.pdf.
- ↑ Kleinman, Mark (3 May 2022). "GSK's £45bn Panadol and Sensodyne-maker Haleon in talks to hire banks". Sky News. https://news.sky.com/story/gsks-45bn-panadol-and-sensodyne-maker-haleon-in-talks-to-hire-banks-12604875.
- ↑ 8.0 8.1 Shane, Daniel (19 December 2018). "Advil meet Excedrin: Pfizer and GSK are merging their consumer healthcare businesses". CNN. https://edition.cnn.com/2018/12/19/business/pfizer-gsk-healthcare/index.html.
- ↑ "Haleon Won't Indemnify Pfizer, GSK Over Zantac. Shares Are Up.". Barron's. 20 September 2022. https://www.barrons.com/articles/haleon-wont-indemnify-pfizer-gsk-zantac-51663686390.
- ↑ Donnellan, Aimee (9 June 2022). "GSK castoff starts life with target on its back". Reuters. https://www.reuters.com/breakingviews/gsk-castoff-starts-life-with-target-its-back-2022-06-09/.
- ↑ Jolly, Jasper (19 January 2022). "Unilever will not increase £50bn offer for GSK consumer arm". The Guardian. https://www.theguardian.com/business/2022/jan/19/unilever-will-not-increase-50bn-offer-for-gsk-consumer-arm.
- ↑ "Nestle Eyed Biggest-Ever Deal in Aborted Move for GSK Unit". Bloomberg News. 25 May 2022. https://www.bloomberg.com/news/articles/2022-05-25/nestle-eyed-biggest-ever-deal-in-aborted-move-for-gsk-consumer#xj4y7vzkg.
- ↑ Tse, Crystal; Nair, Dinesh; David, Ruth (24 February 2023). "GSK Spinoff Haleon Explores Potential $600 Million Sale of ChapStick Brand". Bloomberg. https://archive.today/20230224231835/https://www.bloomberg.com/news/articles/2023-02-24/gsk-spinoff-haleon-is-said-to-explore-sale-of-chapstick-brand?leadSource=uverify%20wall#selection-3471.0-3471.74.
- ↑ "GSK raises $1.1 billion from Haleon stake sale" (in en). Reuters. 2023-10-06. https://www.reuters.com/markets/deals/gsk-raises-886-mln-pounds-haleon-stake-sale-2023-10-06/.
- ↑ "GSK raises $1.24 bln from latest Haleon stake sale" (in en). Reuters. 2024-01-17. https://www.reuters.com/markets/deals/gsk-sell-32-stake-spin-off-haleon-2024-01-16/.
- ↑ 16.0 16.1 "Update: Proposed demerger of the Consumer Healthcare business from GSK to form Haleon". GSK. https://www.gsk.com/en-gb/media/press-releases/update-proposed-demerger-of-the-consumer-healthcare-business-from-gsk-to-form-haleon/.
- ↑ "Our Consumer Healthcare Brands". Haleon. https://www.haleon.com/our-brands/. Retrieved 19 July 2022.
External links
- Business data for Haleon:
 |  |
